Reborn Redx Inks Global Licensing Deal With AstraZeneca

AZ Buys Rights To Porcupine Inhibitor For Fibrotic Diseases

04 Aug 2020

• By Sten Stovall

AstraZeneca will take Redx's RXC006 into clinical development, targeting fibrotic diseases, giving valuable credibility to the biotech’s Wnt pathway hypothesis.

Signpost — Redx Has Come A Long Way Since Exiting Insolvency In 2017 • Source: Shutterstock

Redx Pharma Plc has continued its three-year revival by inking a lucrative deal with AstraZeneca PLC under which the UK’s biggest pharma will take the biotech’s porcupine inhibitor RXC006 into clinical development, targeting fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).

The deal, announced on 4 August, grants AstraZeneca exclusive global rights to develop and commercialize RXC006. It gives Redx –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Deal Watch: Novartis Hopes To Ace Inflammatory Disease With Matchpoint Tie-Up

25 Jul 2025

• By Joseph Haas, Lisa Takagi, and Manas Mishra

Plus deals involving Lilly/Gate Bioscience, Concentra/iTeos, Nicox/Kowa, Ajax/Schrodinger, I-Mab/Bridge Health, Otsuka/Cantargia, JCR/Acumen and more.

Gateway To Africa: Natco Bids For 35.75% Of Adcock Ingram

24 Jul 2025

• By Anju Ghangurde

Natco to buy out Adcock Ingram’s minority shareholders in what’s possibly its biggest M&A investment, opening up substantial opportunities in South Africa and the region. If the offer goes through, it will result in the delisting of Adcock, with Bidvest and Natco co-owning the firm.

Scrip M&A Podcast: Is Biopharma M&A In A Holding Pattern Or A ‘New Normal’

23 Jul 2025

• By Joseph Haas

Scrip discusses the latest M&A activity and trends with CEO Shawn Titcomb of Allele Capital and Cheryl Reicin, a partner focused on international life sciences activity at Mintz.